Document:

EX-10.17

 Exhibit 10.17 

Asante Solutions, Inc. 

Non-Employee Director Compensation Policy 

The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Asante Solutions, Inc., a Delaware corporation (the
“Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries
(“Outside Directors”). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as set forth below: 

 

	 	I.	Cash Retainers 

  

	 	(a)	Annual Retainer for Board Membership: $35,000 for general availability and participation in person and telephonic meetings of our Board of Directors. 

 

	 	(b)	Additional Retainers for Committee Membership: 

  

					
	 Audit Committee Chairperson:
	  	$	15,000	  
		
	 Audit Committee member:
	  	$	7,500	  
		
	 Compensation Committee Chairperson:
	  	$	10,000	  
		
	 Compensation Committee member:
	  	$	5,000	  
		
	 Nominating and Corporate Governance Committee Chairperson:
	  	$	7,000	  
		
	 Nominating and Corporate Governance Committee member:
	  	$	3,500	  

  

	 	(c)	Additional Retainers for Chairperson of the Board: $25,000 to acknowledge the additional responsibilities and time commitment of the Chairperson role. 

 

	 	II.	Equity Retainers 

 All grants of equity retainer awards to Outside Directors pursuant to this
Policy will be automatic and nondiscretionary and will be made in accordance with the following provisions: 
 (a) Value. For
purposes of this Policy, “Value” means with respect to (i) any award of stock options the grant date fair value of the option (i.e., Black-Scholes value) determined in accordance with the reasonable assumptions and
methodologies employed by the Company for calculating the fair value of options under ASC 718; and (ii) any award of Restricted Stock Units the product of (A) the fair market value of one share of the Company’s common stock on the
grant date, and (B) the aggregate number of shares pursuant to such award. 
 (b) Revisions. The Compensation Committee in its
discretion may change and otherwise revise the terms of awards to be granted under this Policy, including, without limitation, the number of shares subject thereto, for awards of the same or different type granted on or after the date the
Compensation Committee determines to make any such change or revision. 

 (c) Sale Event Acceleration. In the event of a Sale Event (as defined in the
Company’s 2015 Stock Option and Incentive Plan), the equity retainer awards granted to Outside Directors pursuant to this Policy shall become 100% vested and exercisable. 

(d) Initial Grant. Upon initial election to the Board, each new Outside Director will receive an initial, one-time grant of a
non-statutory stock option (the “Initial Grant”) equal to 0.075% of the Company’s fully-diluted outstanding stock after the Company’s initial public offering, with an exercise price equal to the closing price of the
Company’s common stock on the date of grant, and a term of ten years, that vests annually over three years; provided, however, that all vesting ceases if the director resigns from our Board of Directors or otherwise ceases to serve as a
director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. This Initial Grant applies to Outside Directors who are first elected to the Board effective as of or subsequent to the Company’s initial
public offering. 
 (e) Annual Grant. On the date of the Company’s Annual Meeting of Stockholders, each Outside Director who is
re-elected to the Board of Directors at the Annual Meeting will receive a grant of a non-statutory stock option on the date of such Annual Meeting (the “Annual Grant”) equal to 0.025% of the Company’s fully-diluted outstanding
stock after the Company’s initial public offering, with an exercise price equal to the closing price of the Company’s common stock on the date of grant, and a term of ten years, that vests in full on the one-year anniversary of the grant
date; provided, however, that all vesting ceases if the director resigns from our Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. 

 

	 	III.	Expenses 

 The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside
Directors in attending meetings of the Board or any Committee thereof. 
  

			
	Date Policy Approved:		     December 10, 2014EX-10.18

 Exhibit 10.18 

ASANTE SOLUTIONS, INC. 

COMMON STOCK PURCHASE AGREEMENT 

THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of January 21, 2015, by and among Asante Solutions,
Inc., a Delaware corporation (the “Company”) and the investors listed on Schedule A hereto (each an “Investor” and together, the “Investors”). 

THE PARTIES HEREBY AGREE AS FOLLOWS: 

1. Purchase and Sale of Stock. 

1.1 Sale and Issuance of Common Stock. Subject to the terms and conditions of this Agreement, each Investor agrees, severally and not
jointly, to purchase from the Company, and the Company agrees to sell and issue to the Investors, an aggregate of $17.1 million of shares (the “Shares”) of Common Stock of the Company (the “Common Stock”), in the
individual amounts set forth opposite such Investor’s name on Schedule A hereto at a price per share (the “Purchase Price”) equal to the per share initial public offering price set forth on the cover of the final prospectus
used in the IPO (as defined below). “IPO” shall mean the issuance and sale of shares of Common Stock by the Company, pursuant to an Underwriting Agreement to be entered into by and among the Company, Leerink Partners LLC and Cowen
and Company, LLC, as representatives of the several underwriters named therein (the “Underwriters”), to the Underwriters in connection with the Company’s initial public offering pursuant to the Company’s Registration
Statement on Form S-1 (File No. 333-201164). 
 1.2 Closing. The purchase and sale of the Shares shall take place at the
location and at the time of the closing of the IPO (which time and place are designated as the “Closing”). At the Closing, each Investor shall make payment of the purchase price of the Shares by wire transfer in immediately
available funds to the account specified by the Company against delivery to such Investor of the Shares registered in the name of such Investor, which Shares shall be uncertificated shares. 

2. Registration Rights. At the Closing, in connection with the purchase of the Shares, the Amended and Restated Investors’ Rights
Agreement dated September 3, 2014 by and among the Company and the Investors (as defined therein) (the “Rights Agreement”), shall be amended by the Amendment to Amended and Restated Investors’ Rights Agreement in
substantially the form attached hereto as Exhibit A (the “Amendment to Rights Agreement”), solely for the purposes of providing the Investors with certain registration rights with respect to the Shares as set forth in the
Amendment to Rights Agreement. 
 3. Representations and Warranties of the Company. The Company hereby represents and warrants to
each Investor, severally and not jointly, that as of the date hereof and as of the date of the Closing: 
 3.1 Organization, Good
Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of 

 
Delaware and has all requisite corporate power and authority to carry on its business as now conducted. The Company is duly qualified to transact business and is in good standing in each
jurisdiction in which the failure to so qualify would have a material adverse effect on its business or properties. 
 3.2
Authorization. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Agreement and the Amendment to Rights Agreement, the performance of all
obligations of the Company hereunder and thereunder, and the authorization, issuance, sale and delivery of the Shares being sold hereunder has been taken or will be taken prior to the Closing, and this Agreement and the Amendment to Rights Agreement
constitute valid and legally binding obligations of the Company, enforceable in accordance with their respective terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general
application affecting enforcement of creditors’ rights generally (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, and (iii) to the extent the indemnification
provisions contained in the Rights Agreement may be limited by applicable federal or state securities laws. 
 3.3 Valid Issuance of
Common Stock. The Shares being purchased by the Investors hereunder, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid and
nonassessable and will be free of restrictions on transfer other than restrictions on transfer under applicable state and federal securities laws or as contemplated hereby or by the Rights Agreement. 

3.4 Compliance with Other Instruments. The Company is not in violation or default of any provision of its Amended and Restated
Certificate of Incorporation or Bylaws, or in any material respect of any instrument, judgment, order, writ, decree or contract to which it is a party or by which it is bound, or, to its knowledge, of any provision of any federal or state statute,
rule or regulation applicable to the Company. The execution, delivery and performance of this Agreement and the Amendment to Rights Agreement, and the consummation of the transactions contemplated hereby and thereby will not result in any such
violation or default or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument, judgment, order, writ, decree or contract or an event that results in the
creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization, or approval applicable to the Company, its business or
operations or any of its assets or properties. 
 3.5 Private Placement. Assuming the accuracy of the Investors’ representations
and warranties set forth in Section 4 of this Agreement, no registration under the Securities Act is required for the offer and sale of the Shares by the Company to the Investors under this Agreement. 

  
 2 

 4. Representations and Warranties of the Investors. Each Investor, severally and not
jointly, hereby represents and warrants that as of the date hereof and as of the date of the Closing: 
 4.1 Authorization. Such
Investor has full power and authority to enter into this Agreement and the Amendment to Rights Agreement, and each such agreement constitutes its valid and legally binding obligation, enforceable in accordance with its terms except (i) as
limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies and (iii) to the extent the indemnification provisions contained in the Rights Agreement may be limited by applicable federal or state securities laws. 

4.2 Purchase Entirely for Own Account. This Agreement is made with each Investor in reliance upon such Investor’s representation
to the Company, which by such Investor’s execution of this Agreement such Investor hereby confirms, that the Shares to be received by such Investor will be acquired for investment for such Investor’s own account, not as a nominee or agent,
and not with a view to the distribution of any part thereof, and that such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same, except as permitted by applicable federal or state securities
laws. By executing this Agreement, such Investor further represents that such Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person,
with respect to any of the Shares. 
 4.3 Disclosure of Information. Such Investor believes it has received all the information it
considers necessary or appropriate for deciding whether to purchase the Shares. Such Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering
of the Shares and the business, properties, prospects and financial condition of the Company. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 3 of this Agreement or the right
of the Investors to rely thereon. 
 4.4 Investment Experience. Such Investor is an investor in securities of companies in the
development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the
investment in the Shares. If other than an individual, such Investor also represents it has not been organized for the purpose of acquiring the Shares. 

4.5 Accredited Investor. Such Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as
presently in effect. 
 4.6 Restricted Securities. Such Investor understands that the Shares will be characterized as
“restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be
resold without registration under the Securities Act, only in certain limited circumstances. In this connection, such Investor represents that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed
thereby and by the Securities Act. 

  
 3 

 4.7 Legends. It is understood that the Shares may bear one or all of the following
legends: 
 (a) “These securities have not been registered under the Securities Act of 1933, as amended. They may not be
sold, offered for sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or an opinion of counsel satisfactory to the Company that such registration is not required or unless
sold pursuant to Rule 144 of such Act.” 
 (b) Any legend required by applicable state “blue sky” securities
laws, rules and regulations. 
 4.8 Lock-Up Agreement; Market Stand-Off Agreement. Each Investor has executed and delivered to the
Underwriters in connection with the IPO a lock-up agreement in substantially the form attached hereto as Exhibit B (the “Lock-Up Agreement”). Such Lock-Up Agreement is in full force and effect, and following the consummation
of the transactions contemplated by this Agreement will remain in full force and effect, including with respect to the Shares and related limits on the ability to exercise the registration rights described in Section 2 hereof. Further,
each Investor is bound by the market stand-off agreement set forth in Section 2.10 of the Rights Agreement, and such agreement is in full force and effect, and following the consummation of the transactions contemplated by this Agreement
will remain in full force and effect, including with respect to the Shares. 
 5. Conditions of Investors’ Obligations at
Closing. The obligations of each Investor under Section 1.1 of this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions. 

5.1 Representations and Warranties. The representations and warranties of the Company contained in Section 3 shall be true
on and as of the Closing, except as would not reasonably be expected to have a material adverse effect on the Company. 
 5.2 Public
Offering Shares. The Underwriters shall have purchased, concurrently with the purchase of the Shares by the Investors hereunder, the Initial Securities (as defined in the Underwriting Agreement) at the same purchase price (less any underwriting
discounts or commissions) per share payable by the Investors hereunder. 

  
 4 

 6. Compliance with Securities Laws and Regulations. Notwithstanding anything to the
contrary contained in this Agreement, the Company is not undertaking the obligation to commit any act in violation of the Securities Laws and Regulations (as defined below) or any other laws, rules and regulations applicable to the IPO, or over any
objection of the Commission or the Financial Industry Regulatory Authority, Inc. and any successor organizations or entities thereto (“FINRA”). In the event that by reason of the provisions of this Section 6, in the
Company’s reasonable judgment the transactions contemplated by this Agreement would, based on the advice of securities counsel for the Company and concurred in by counsel for the Underwriters after consultations with the Commission and/or
FINRA, be deemed invalid as a private placement under the Act for any reason (including but not limited to by reason of the doctrine of “integration” with the IPO) or would otherwise conflict with any Securities Laws and Regulations or
give rise to any other legal impediment or legal requirement that would prevent or materially delay the consummation of or unreasonably interfere with the IPO or the purchase of shares of Common Stock as contemplated in Section 1.1
hereof (each such event, a “Termination Event”), then this Agreement shall terminate immediately, unless such Termination Event can be cured with reasonable diligence within ten days after the Company has determined that such
Termination Event has occurred. “Securities Laws and Regulations” means (x) all applicable federal, state or other securities laws (including but not limited to the Securities Act, as amended from time to time, and the rules
and regulation from time to time promulgated thereunder, the Securities Exchange Act of 1934, as amended from time to time, and the rules and regulation from time to time promulgated thereunder or the rules and regulations of any securities
exchange) and (y) all rules and regulations of FINRA or any other self-regulatory organization that are applicable to the Company, the Investors or any Underwriter, as applicable. 

7. Termination. Other than as provided in Section 6 hereof, this Agreement shall automatically terminate upon the earliest
to occur of (i) the written consent of the Company and the Investors, (ii) the withdrawal by the Company of the Registration Statement, (iii) following the execution of the Underwriting Agreement, the termination of such Underwriting
Agreement in accordance with its terms, or (iv) May 31, 2015. 
 8. Miscellaneous. 

8.1 Survival of Warranties. The warranties, representations and covenants of the Company and the Investors contained in or made
pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of the Investors or the Company. 

8.2 Assignment; Successors and Assigns. No Investor may assign this Agreement or any of its rights or obligations hereunder without the
prior written consent of the Company, except to any general partners, limited partners, members, direct or indirect subsidiaries of such Investor that are at least 50% controlled by such Investor and affiliates of such Investor, and/or any venture
capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or is under common investment management with, such Investor; provided, however that any such assignee shall agree in
writing with the Company to be bound by all of the terms and conditions of this Agreement, including, but not 

  
 5 

 
limited to Section 4 hereof, and execute and deliver to the Underwriters a Lock-up Agreement. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any Shares). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

8.3 Governing Law. This Agreement shall be governed by in all respects by the internal laws of the State of Delaware, without regard to
principles of conflicts of law. 
 8.4 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. 
 8.5 Titles and Subtitles. The
titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

8.6 Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively
given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by notice given in accordance with this
Section 8.6). 
 8.7 Finder’s Fee. Each party represents that it neither is nor will be obligated for any
finders’ fee or commission in connection with this transaction. Each Investor agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of a finders’ fee (and the costs and
expenses of defending against such liability or asserted liability) for which such Investor or any of its officers, partners, employees, or representatives is responsible. The Company agrees to indemnify and hold harmless each Investor from any
liability for any commission or compensation in the nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is
responsible. 
 8.8 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Shares purchased hereunder. Any amendment or waiver
effected in accordance with this section shall be binding upon each holder of any Shares purchased under this Agreement at the time outstanding, each future holder of all such Shares, and the Company. 

  
 6 

 8.9 Severability. If one or more provisions of this Agreement are held to be unenforceable
under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

8.10 Corporate Securities Law. THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS
EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 

8.11 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no
party shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically set forth herein or therein. 

[Remainder of page intentionally left blank] 

  
 7 

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of
the date first above written. 
  

			
	ASANTE SOLUTIONS, INC.
		
	By:		 /s/ David Thrower

	Name:		David Thrower
	Title:		 Chief Executive Officer

		
	Address:		352 East Java Drive
			Sunnyvale, CA 94089

  
 SIGNATURE PAGE TO
ASANTE SOLUTIONS, INC. 
 COMMON STOCK PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of
the date first above written. 
  

			
	INVESTORS:
	
	Thomas, McNerney & Partners II, L.P.
		
	By:	 	Thomas, McNerney & Partners II, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ James Thomas

	Name:	 	James Thomas
	Title:	 	Manager
	
	TMP Nominee II, LLC
		
	By:	 	 /s/ James Thomas

	Name:	 	James Thomas
	Title:	 	Manager
	
	TMP Associates II, L.P.
		
	By:	 	Thomas, McNerney & Partners II, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ James Thomas

	Name:	 	James Thomas
	Title:	 	Manager
	
	Address:
	60 South 6th Street
	Suite 3620
	Minneapolis, MN 55402
	
	Fax: [redacted]
	E-mail: [redacted]

  
 SIGNATURE PAGE TO
ASANTE SOLUTIONS, INC. 
 COMMON STOCK PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	De Novo Ventures III, L.P.
		
	By:	 	De Novo Management III, LLC
	Its:	 	General Partner
		
	By:	 	 /s/ Joe Mandato

	Joe Mandato, Managing Director
	
	Address:
	14612 Big Basin Way
	Suite B
	Saratoga, CA 95070
	
	E-mail: [redacted]

  
 SIGNATURE PAGE TO
ASANTE SOLUTIONS, INC. 
 COMMON STOCK PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	NOVO A/S
		
	By:	 	 /s/ Thomas Dyrberg

		
	Name:	 	 Thomas Dyrberg MD

		
	Title:	 	 Senior Partner

		
	Address:	 	Tuborg Havnevej 19
		 	DK 2900 Hellerup
		 	Denmark
		 	Attn: Heather Ludvigsen
	Fax:
	E-mail: [redacted]

  
 SIGNATURE PAGE TO
ASANTE SOLUTIONS, INC. 
 COMMON STOCK PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first above
written. 
  

					
	INVESTORS:	 	
		
	Sunstone Life Science Ventures Fund I K/S	 	
			
	By:	 	 /s/ Peter Benson
	 	 /s/ Merete Moller

			
	Name:	 	 Peter Benson
	 	 Merete Moller

			
	Title:	 	 Managing Partner
	 	 Partner

			
	Address:	 	Lautrupsgade 7, 5	 	
		 	2100 Copenhagen	 	
		 	Denmark	 	
		 	Attn: Mr. Peter Benson	 	
		
	Fax: [redacted]	 	
	E-mail: [redacted]	 	
	Copy: [redacted]	 	

  
 SIGNATURE PAGE TO
ASANTE SOLUTIONS, INC. 
 COMMON STOCK PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first above
written. 
  

			
	INVESTORS:
	
	SeeD Capital Denmark K/S
		
	By:	 	 /s/ Ulla Brockenhuus-Schack

		
	Name:	 	 Ulla Brockenhuus-Schack

		
	Title:	 	 Managing Partner

		
	By:	 	 /s/ Lars Anderson

		
	Name:	 	 Lars Anderson

		
	Title:	 	 General Partner

		
	Address:	 	Diplomvej 381, DK-2800 Kgs. Lyngby
		 	Attn: Ulla Brockenhuus-Schack
	Fax: [redacted]
	E-mail: [redacted]

  
 SIGNATURE PAGE TO
ASANTE SOLUTIONS, INC. 
 COMMON STOCK PURCHASE AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first above
written. 
  

					
	INVESTORS:
	
	Lundbeckfond Invest A/S
		
	By:	 	 /s/ Lene Skole

	Name:	 	Lene Skole
	Title:	 	CEO
		
	By:	 	 /s/ Mette Kirstine Agger

	Name:	 	Mette Kirstine Agger
	Title:	 	Managing Partner
		
		 	Address: Scherfigsvej 7,
		 		 	DK-2100 København Ø
		 		 	Denmark
		 	Fax:	 	[redacted]
		 	E-mail:	 	[redacted]

  
 SIGNATURE PAGE TO
ASANTE SOLUTIONS, INC. 
 COMMON STOCK PURCHASE AGREEMENT 

 Schedule A 
  

					
	 Investor
	  	Purchase Amount (in dollars)	 
	 De Novo Ventures III, L.P.
	  	$	1,000,000	  
		
	 Lundbeckfond Invest A/S
	  	$	6,000,000	  
		
	 Novo A/S
	  	$	5,500,000	  
		
	 SeeD Capital Denmark K/S
	  	$	1,600,000	  
		
	 Sunstone Life Science Ventures Fund I K/S
	  	$	2,000,000	  
		
	 Thomas, McNerney & Partners II, L.P.
	  	$	991,300	  
		
	 TMP Nominee II, LLC
	  	$	5,000	  
		
	 TMP Associates II, L.P.
	  	$	3,700	  
		
	 TOTAL
	  	$	17,100,000	  
		  	  
	  
	 

 Exhibit A 

Amendment to Rights Agreement 

 Exhibit B 

Lock-Up Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]